2025
Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis
Balter D, Cao Y, Garritano J, Micevic G, Sanchez A. Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis. Clinical Nephrology - Case Studies 2025, 13: 8-12. PMID: 39949516, PMCID: PMC11823000, DOI: 10.5414/cncs111578.Peer-Reviewed Original ResearchNon-uremic calciphylaxisDermatological complicationsAlcohol-associated cirrhosisPainful skin lesionsAcute kidney injurySodium thiosulfate therapyInfectious complicationsKidney injuryTreatment optionsSkin biopsiesHepatic encephalopathyWork-upSkin lesionsCalciphylaxisCirrhosisComplicationsThiosulfate therapyAlcohol associationsPatientsTreatmentBiopsyPrognosisTherapyLesionsEncephalopathy
2024
S1849 Are Patients With MASH Cirrhosis or Alcohol-Associated Cirrhosis More Likely to Develop Hepatic Hydrothorax? A National Transplant Database Analysis
Boateng S, Zahrawi F, Jalalzai M, Banini B. S1849 Are Patients With MASH Cirrhosis or Alcohol-Associated Cirrhosis More Likely to Develop Hepatic Hydrothorax? A National Transplant Database Analysis. The American Journal Of Gastroenterology 2024, 119: s1331-s1331. DOI: 10.14309/01.ajg.0001036764.22289.36.Peer-Reviewed Original Research
2023
Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol use
2021
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis
Sehrawat T, Arab J, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro‐Corcuera A, Dasgupta D, Liao C, He L, Mauer A, Avitabile E, Ventura‐Cots M, Bataller R, Sanyal A, Chalasani N, Heimbach J, Watt K, Gores G, Gines P, Kamath P, Simonetto D, Hu T, Shah V, Malhi H. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology 2021, 73: 571-585. PMID: 32246544, PMCID: PMC7541595, DOI: 10.1002/hep.31256.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAlcohol-associated cirrhosisAlcoholic hepatitisAH subjectsHealthy controlsHeavy drinkersLiver diseaseEtiology of ESLDEV concentrationEnd-stage liver disease (MELD) scoreExtracellular vesiclesRisk profilingPathogenesis of AHLiver Disease scoreCholestatic liver diseaseNonalcoholic steatohepatitisRisk stratificationClinical criteriaPrognostic performanceDisease scoreDiagnostic biomarkersDisease controlEV countsDiseaseDrinkers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply